Hospital-based CAR-T manufacturing at cost through a public network
Academic hospitals can already make CAR-T cells for a fraction of the commercial price. A public network would scale that so more patients can be treated for less.
Point-of-care manufacturing of CAR-T and other autologous cell therapies in a network of accredited academic hospitals, using shared vectors, harmonised processes and closed automated systems, with regulatory approval as a hospital-exemption or public product rather than a commercial licence. Spain's ARI-0001 (Hospital Clínic Barcelona) was approved by the national agency as a hospital-made CD19 CAR-T at a reported cost far below commercial products; India and Brazil have followed with domestic academic products. A network would share process, quality and pharmacovigilance and could supply public health systems at cost.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
Pages like this
not linked directly; found by shared links- IdeaHospital-made CAR-T under one shared regulatory master file
Shares BCMA, CD19, Prices and value, Manufacturing cost and time for living and radioactive medicines.
- IdeaPlan the second CAR-T target before the first one is lost
Shares BCMA, Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- IdeaIn vivo CAR-T manufactured and priced like a generic biologic
Shares BCMA, CD19, Prices and value, Manufacturing cost and time for living and radioactive medicines.
- InstitutionHadassah Medical Center
Shares BCMA, CD19, Manufacturing cost and time for living and radioactive medicines, Multiple myeloma.
- CompanyCaribou Biosciences
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares BCMA, CD19, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- InstitutionHospital Clínic de Barcelona / IDIBAPS
Shares BCMA, CD19, Prices and value, Manufacturing cost and time for living and radioactive medicines.